Methylnaltrexone for Refractory Opioid-Induced Constipation in Hospitalized Cancer Patients —A Highly Effective Treatment (F415A)

Methylnaltrexone is a peripherally acting mu-opioid receptor antagonist that has been studied in cancer and non-cancer patients with opioid-induced constipation (OIC), but only in the outpatient setting. For hospitalized patients with cancer pain and laxative-refractory OIC, its effectiveness is unknown.

Source: Journal of Pain and Symptom Management - February 23, 2021 Category: Palliative Care Authors: David Harris, David Z. Kalir, Cory A. Chevalier, Krista R. Dobbie, Flannery Fielding, Ruth L. Lee, Ahed Makhoul, Susan McInnes, Kyle Neale, Lisa Rybicki, Melanie Robbins-Ong, Kathleen Neuendorf, Sina Najafi Source Type: research